Aller au contenu principal

 Articles scientifiques

What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?

Auteurs : Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 2783-2788

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Auteurs : Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Devlin N, Dorme L, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Kluetz PG, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, OConnor D, Oliver K, Piault-Louis E, Piccart-Gebhart M, Quinten C, Reijneveld JC, Schürmann C, Smith AW, Soltys KM, Taphoorn MJB, Velikova G, Bottomley A
Année : 2020
Journal : Lancet Oncol
Volume : 21
Pages : e83-e96

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Auteurs : Pondé N, Ameye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E
Année : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Auteurs : Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber Rd, Piccart-Gebhart M, Mobus V, de Azambuja E
Année : 2020
Journal : Clin Breast Cancer
Volume : 20
Pages : 174-181.e3

Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer.

Auteurs : Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Pogoda K, Velikova G, Bjelic-Radisic V, Cardoso F, Brain E, Ignatiadis M, Piccart-Gebhart M, Van Tienhoven G, Mansel R, Wildiers H, Bottomley A
Année : 2020
Journal : Eur J Cancer
Volume : 125
Pages : 69-82

Post-Mastectomy Radiation Therapy in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer Patients: Analysis of the HERA Trial.

Auteurs : Abi Jaoude J, de Azambuja E, Makki M, Tamim H, Tfayli A, Geara F, Piccart-Gebhart M, Poortmans P, Zeidan YH
Année : 2020
Journal : Int J Radiat Oncol Biol Phys
Volume : 106
Pages : 503-510

A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

Auteurs : de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber Rd, Piccart-Gebhart M, Suter T
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 179
Pages : 161-171

Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.

Auteurs : Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F
Année : 2020
Journal : Acta Oncol
Volume : 59
Pages : 1438-1446

Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.

Auteurs : Jacob L, Witteveen A, Beumer I, Delahaye L, Wehkamp D, Van den Akker J, Snel M, Chan B, Floore A, Bakx N, Brink G, Poncet C, Bogaerts J, Delorenzi M, Piccart-Gebhart M, Rutgers E, Cardoso F, Speed T, van t Veer L, Glas A
Année : 2020
Journal : Commun Biol
Volume : 3
Pages : 397

Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.

Auteurs : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart M, de Azambuja E
Année : 2020
Journal : J Natl Cancer Inst

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

Auteurs : Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A
Année : 2020
Journal : Clin Colorectal Cancer

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Auteurs : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart M, Biganzoli E
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 2883-2891

<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.

Auteurs : Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, Robertson JFR, Gradishar W, Piccart M, Schiavon G, Bliss JM, Dowsett M, Johnston SRD, Chia SK
Année : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 5172-5177

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.

Auteurs : Demicheli R, Desmedt C, Retsky M, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Année : 2020
Journal : Breast
Volume : 52
Pages : 64-70

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome.

Auteurs : Venet D, Fimereli D, Rothé F, Boeckx B, Maetens M, Majjaj S, Rouas G, Capra M, Bonizzi G, Contaldo F, Galant C, Piccart M, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Sotiriou C
Année : 2020
Journal : EBioMedicine
Volume : 56
Pages : 102793

Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.

Auteurs : Caballero C, Piccart M
Année : 2020
Journal : Ann Oncol
Volume : 31
Pages : 1083-1084

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Auteurs : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart M, de Azambuja E
Année : 2020
Journal : Breast Cancer Res Treat
Volume : 181
Pages : 199-209

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.

Auteurs : Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Láng I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E
Année : 2020
Journal : Br J Cancer
Volume : 122
Pages : 1453-1460

The Legacy of Professor Aron Goldhirsch.

Auteurs : Gelber Rd, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart-Gebhart M, Curigliano G
Année : 2020
Journal : Ann Oncol

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.

Auteurs : Delaloge S, Piccart M, Rutgers E, Litière S, van t Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F
Année : 2020
Journal : J Clin Oncol
Volume : 38
Pages : 1186-1197